Personalized hypertension management aims to optimize therapeutic efficacy while minimizing adverse effects by selecting the most suitable medication for each patient. Pharmacogenetic research plays a critical role in this approach by identifying genetic variants that influence interindividual differences in drug response. However, translating these findings into clinical practice requires validation in specific populations to confirm known associations and potentially uncover novel, population-specific variants. This study investigates two single nucleotide polymorphisms (SNPs): rs3814995 in the NPHS1 gene and rs2295490 in the TRIB3 gene, both of which are relevant to antihypertensive therapy. The NPHS1 gene encodes a member of the immunoglobulin family of cell adhesion molecules with the role in glomerular filtration barrier in the kidney and may modulate the response to angiotensin II receptor blockers such as losartan. The TRIB3 gene encodes a pseudokinase that inhibits AKT kinase by direct binding, potentially affecting the action of angiotensin-converting enzyme inhibitors like imidapril. Genotype frequencies for both SNPs were analyzed in a local cohort to evaluate potential associations with the efficacy of prescribed antihypertensive agents. Identifying such pharmacogenetic associations may enable the development of personalized treatment protocols that improve patient adherence and long-term blood pressure control. The results contribute to a growing body of evidence supporting the integration of genetic screening into hypertension management and provide a foundation for future clinical studies focused on individualized therapy.